Table 1: Baseline characteristics of study participants.

Characteristics Immune Discordant Response Patients
(n=28)
Immune Concordant Response Patients
(n=76)
P
values
Age (years)
Mean (SD)
Median (IQR)
52 ± 14 (30-80)
49 (40-59)
45 ±12 (18-71)
44 (36-52)
0.03
Male [n (%)] 17 (60) 42 (55) 0.66
Hemoglobin (g/dL)
Mean (SD)
Median (IQR)
12.1 ± 2.3 (8-16)
12 (10-14)
12.4 ± 2.1 (9-17)
12.5 (10.5-14)
0.76
Platelet count (x109/L)
Mean (SD)
Median (IQR)
265 ± 91 (140-490)
234 (197-317)
256 ± 101 (170-686)
253 (202-299)
0.68
CD4+ T cell count (cells/μL)
Mean (SD)
Median (IQR)
10 6 ± 107 (30-343)
89 (13-164)
350 ± 277 (90-1177)
271 (75-444)
0.001
CD8+ T cell count (cells/μL)
Mean (SD)
Median (IQR)
740 ± 674 (77-2780)
459 (347-923)
996 ± 972 (78-7703)
849 (492-1120)
0.19
CD4/CD8 ratio
mean (SD)
Median (IQR)
0.31 ± 0.2 (0.07-0.7)
0.1 (0.04-0.25)
0.46 ± 0.3 (0.1-1.19)
0.27 (0.12-0.51)
0.04
CD19+ cell count (cells/μL)
Mean (SD)
Median (IQR)
141 ± 138 (14-479)
95 (51-188)
194 ± 184 (19-1042)
147 (66-257)
0.17
CD56+ cell count (cells/μL)
Mean (SD)
Median (IQR)
89 ± 73 (14-256)
67(32-119)
185 ± 157 (10-996)
160(78-255)
0.002
Co-infection with HCV [n (%)] 5 (18) 9 (12) 0.42
HIV viral load (log10 copies/mL)
Mean (SD)
Median (IQR)
4.2 ± 0.98 (2.6-6)
4.42 (3.5-4.8)
4.1 ± 1.3 (2.6-6.9)
4.3 (2.6-5.1)
0.35
Duration on ART (year)
Mean (SD)
Median (IQR)
8 ± 3 (5-11)
8 (5-13)
7.8 ± 3 (4-11)
8 (4-14)
0.97
Efavirenz-based regimen [n (%)] 22 (78) 56 (73) 0.79
AZT-3TC-based regimen [n (%)] 16 (57) 62 (81) 0.02
Tuberculosis co-infection [n (%)] 3 (10) 6 (7) 0.69

Results are shown as mean, median, Standard Deviation (SD) and Interquartile Range (IQR). HCV: Hepatitis C Virus; HIV: Human Immunodeficiency Virus; ART: Antiretroviral Therapy. AZT: Zidovudine; 3TC: Lamivudine.

Back to Article